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Abstract
Purpose Patients undergoing radiotherapy for prostate cancer
suffer from a variety of symptoms which influence health-
related quality of life. We have developed an application
(Interaktor) for smartphones and tablets for early detection,
reporting and management of symptoms, and concerns during
treatment for prostate cancer. The study evaluates the effect on
symptom burden and quality of life when using the applica-
tion for real-time symptom assessment and management dur-
ing radiotherapy for localized prostate cancer.
Methods A non-randomized controlled study was used at two
university hospitals in Sweden where 64 patients constituted a
control group and 66 patients made up an intervention group.
The intervention group was asked to report symptoms via the
application daily during the treatment as well as 3 weeks after.
The EORTCQLQ-C30 and its module PR25 and the Sense of
Coherence questionnaire were administered at three time
points in both groups.
Results The intervention group rated significantly lower
levels of fatigue and nausea at the end of radiotherapy.
Moreover, they had significantly less burden in emotional
functioning, insomnia, and urinary-related symptoms at the
end of treatment as well as 3 months later compared with the
control group. In the multivariate analyses, with education and
sense of coherence as covariates, the intervention group still
significantly rated emotional functioning (p = 0.007), insom-
nia (p = 0.017), and urinary-related symptoms (p = 0.008) as
better than the control group at T2.
Conclusion Study findings suggest that Interaktor could be an
efficient mHealth tool for facilitating supportive care needs
during cancer treatment.
Keywords Prostate cancer . Radiotherapy . Symptom
reporting . Symptommanagement . Interactive smartphone
application
Introduction
Through early diagnosis and improved therapies for patients
with localized prostate cancer, many men will be cured [1].
The patients typically receive radiotherapy, often in combina-
tion with hormonal treatment, which causes side effects that
significantly may impact the patients’ health-related quality of
life (HRQoL) [2, 3]. During the treatment period, the patients
are mostly cared for as outpatients. This puts demands on both
the patient to be an expert on his own health and on the health
care setting to deliver safe care. One concern is the patients’
unmet needs regarding information and knowledge of symp-
tomsand sideeffects of the illness and its treatment [4].Another
concern is the lack of strategies for symptom management as
well as self-care to alleviate symptom distress following treat-
ment [5, 6]. Therefore, regular symptom assessment and pur-
poseful information regarding self-management activities are
important factors in the management of prostate cancer and
treatment-related consequences [4, 6].
A developing focus in cancer care is to systematically in-
tegrate the collection of patient-reported outcomes (PRO) in
clinical practice as the foundation for care planning and
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evaluation of treatment efficacy [7]. PROs can be any aspect
of a patient’s health status (including symptoms, functioning,
and HRQoL) that is reported by the patient without any inter-
pretation of the responses by a caregiver or anyone else [8].
Studies show that clinical routine use of PROs may facilitate
the detection of problems, provide information on impact of
treatment, monitor quality improvement, enhance patient-
clinician communication, promote shared decision making,
and improve patient satisfaction [9, 10].
Information and communication technology (ICT) is be-
coming an integral part of modern health care [11]. The ICT-
based solutions utilize digital technology access to Internet-
based programs (eHealth) and use of mobile devices, platforms,
and applications (mHealth). These have various purposes, in-
cluding assisting with self-management, delivering real-time
data on a patient’s health condition to both the patient and
caregivers, and storing personal health information in an easily
accessible format [11]. Collecting PROs through different ICT
applications has previously been tested in cancer care with, for
example, touch screens [12] and Web-based systems [13].
Hilarius et al. (2008) support the use of cancer-specific assess-
ments as a means of facilitating discussions of HRQoL issues,
by increasing nurses’ awareness of their patients’ problems. In
a recent RCT, including patients with breast and prostate can-
cer, a Web-based interactive health communication application
was tested [13]. Symptoms during treatment were monitored,
and self-management support, communication with expert can-
cer nurses, and an e-forum with other patients were provided.
The results showed HRQoL scores in slight favor of the inter-
vention group overall, although differences were statistically
significant only for the global symptom distress subscale. In a
study with heart failure patients, self-care was improved
through the use of a mobile phone-based system with instruc-
tions to the patients about how to appropriately modify lifestyle
behaviors [14]. Another study used amobile phone-based ques-
tionnaire for reporting symptoms when receiving chemothera-
py for colorectal, lung, or breast cancer [15]. The findings
showed improved symptom management and communication
between patients and health care professionals, and the patients
also reported that they felt reassured that their symptoms were
monitored while at home. These studies show promising re-
sults, but it has also been suggested that applications for
smartphones are effective tools to involve the patients and en-
hance their notions of participation and respect [16]. However,
interactive smartphone applications facilitating support needs
by exchanging health information in real-time between patients
and nurses have rarely been studied.
Therefore, in co-design with patients and health care per-
sonnel, we have developed [5] and tested [17] an interactive
application (Interaktor) for smartphones and tablets. Daily re-
ports via the application enable instant support from a nurse in
early detection and management of symptoms and concerns in
real-time during treatment for prostate cancer. The project is
conducted in cooperation with Health Navigator, a Swedish
company specializing in health care management and new
innovative care solutions. Interaktor includes symptom as-
sessment, a risk assessment model for alerts directly to a nurse,
continuous access to evidence-based self-care advice, and
links to relevant Web sites directly related to reported symp-
toms and concerns.
Our feasibility study showed high user-friendliness and
acceptability by both patients and nurses when used during
radiotherapy for prostate cancer [17]. The objective of this
study was to evaluate the effect on symptom burden as well
as health-related quality of life when using the application for
real-time symptom assessment and management during adju-
vant radiotherapy for localized prostate cancer.
Methods
Study design and participants
Anon-randomized controlled designwas used including patients
fromtwosites,oneurbanandonerural.Datawascollectedat three
time-points in both an intervention group and a control group
betweenApril 2012 andOctober 2013: at T1 baseline, at T2 after
end of treatment, and at T3 3months after end of treatment.
A total of 130 patients with prostate cancer from two uni-
versity hospitals in Sweden participated in the study: interven-
tion group (IG), n = 66 (77%); control group (CG), n = 64
(80%). The sample size was considered sufficient as com-
pared with a similar study of patients with heart failure, show-
ing that 34 patients/group is enough to reach effect size of 1 in
the main outcome of self-reported health [14].
The study was historically controlled, whereas the data for
the CG was collected first, and when completed, the inclusion
in the IG began (Fig. 1). Inclusion criteria were (1) a localized
prostate cancer (T1c-T3, N0M0); (2) eligibility for curative
radiotherapy (RT); (3) being able to read and understand
Swedish; and (4) being considered physically, psychological-
ly, and cognitively able to participate in the study. The patients
were treated according to the National guidelines for prostate
cancer [18] with external beam radiation therapy (EBRT) 78
Gray/39 fractions with or without a combination of iridium
high-dose-rate brachytherapy (HDR) and neoadjuvant hor-
mone therapy (HT). The patients treated solely with EBRT
were treated for a period of 8 weeks, whereas those who re-
ceived a combination of HDR and the EBRT lasted for
5 weeks. The treatment protocol was the same for both sites.
During RT, the standard care for all patients comprises regular
contact with therapy staff and access to a contact nurse regard-
ing any treatment-related concerns. No regular medical ap-
pointments or other standard procedures are included in the
care during the treatment period. The mean age (range) of all
patients included was 69 years (52–82) (Table 1).
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The patients who were listed for RT at the two sites
were consecutively included in the study. The coordina-
tors at the RT units identified the patients and provided
oral and written information about the study. The re-
searchers subsequently called the patients, and if they
were considered to fulfill the inclusion criteria, they were
asked to participate in the study. Written informed consent
was obtained from all study participants. Ethical approval
was obtained from the Regional Ethical Review Board of
Uppsala University (dnr 2011/256).
The intervention—real-time symptom assessment
The patients in the IG were equipped with a smartphone
and were given thorough instructions how to use the
installed app and an opportunity to send a test report un-
der supervision. The patients were provided with a check-
list including a phone number in case they needed to get
in contact for any technical support. They were asked to
send daily reports at any time point when they felt unwell
for the entire period of RT (5–8 weeks), as well as for the
following 3 weeks after treatment. The patients were in-
formed that during the study period, the alerts (via text
messages) were monitored only during office hours, and
so were instructed to contact the clinic for emergencies
outside those hours. A reminder message was sent if a
report had not been submitted. At the clinic, the nurses
who were the patients’ contact nurses viewed the reported
symptoms via the Web interface and, in case of an alert,
contacted the patient by telephone to discuss the reported
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problems. The patients were also instructed about the self-
care advice and that they could view their own symptom-
history in graphs over time.
The symptom assessment in the application included
15 identified and tested questions regarding the following:
bladder (n = 4) and bowel (n = 4) function, fatigue, pain,
anxiety, distress, sleep, and flushing [5, 17]. The last
question Bother symptoms or concerns to report^ was an
open question providing the opportunity to write a mes-
sage. The structure of the assessments was based on a
standardized symptom and HRQoL questionnaire model
[19]; in other words, the questions addressed occurrence,
frequency, and distress level. For example, BDo you ex-
perience urinary urgency?^ If the answer was yes, the
patient was asked how often it occurs, rated by frequency:
never, sometimes, rather often, or very often; additionally,
they rated how distressing the symptom was: not at all, a
little, rather, or very much. The risk assessment model,
based on symptom occurrence and frequency, sent two
kinds of alerts: yellow and red. For example, a yellow
alert appeared if the patient reported urinary retention
Brather often,^ and a red alert, when the patient reported
urinary retention Bvery often.^ A yellow alert indicated
that the nurse should contact the patient sometime during
Table 1 Clinical and socio-
demographic characteristics of
patients in the intervention group
(n = 66) and the control group
(n = 64)
Intervention group Control group p
Age
mean (SD) 69 (5.8) 69 (6.2) 0.805*
median (range) 70 (53–82) 71 (52–80)
Health Literacy-Index
mean (SD) 318 (609) 476 (855) 0.232*
Living situation, n (%) 0.238**
married/living with partner 49 (75) 47 73
Alone 9 (14) 13 20
Other 8 (11) 4 6
Education level, n (%) 0.017**
Junior compulsory 9 (14) 22 36
Senior high school 23 (36) 17 28
Postgraduate/university 32 (50) 22 36
Occupation, n (%) 0.428**
Working 13 (20) 9 (15)
Retired 47 (71) 50 (78)
Sick leave 1 (1) 1 (1)
Other 5 (8) 4 (6)
Clinical T stage, n (%) 0.622**
1 16 (24) 18 (28)
2 29 (44) 25 (39)
3 17 (26) 20 (31)
Missing 4 (6) 1 (2)
Gleason, n (%) 0.300**
6 10 (15) 5 (8)
7 28 (42) 36 (56)
8 13 (20) 13 (20)
9 14 (21) 7 (11)
10 1 (2) 1 (2)
Missing 2 (3)
Treatment, n (%) 0.130**
Neoadjuvant hormonal therapy (HT) 50 (76) 40 (62)
External beam radiotherapy (EBRT) 20 (30) 22 (34)
Brachytherapy combined with EBRT 46 (70 44 (66)
* Tested for differences by Student’s t test
** Tested for differences by χ2 statistics
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the same day. A red alert had a higher priority, meaning
contact should be made within an hour.
Measurements
Medical and demographic data were collected at baseline in
both groups from the medical records. A questionnaire mea-
suring Health Literacy, defined to cover cognitive and social
skills that determine the motivation and ability to acquire un-
derstand and use information in a way that promotes and
maintains good health [20], was included at baseline. A
Health Literacy-Index was categorized from a tested scale
[21] on three levels where sums <100 equals sufficient health
literacy, >110 but <1000 equals problematic health literacy,
and >1000 equals inadequate health literacy [22].
EORTC QLQ-C30 and EORTC QLQ-PR25
The EORTC QLQ-C30 was developed for measurement of
HRQoL in cancer patients and has been extensively validated
[23]. The 30-item questionnaire incorporates five functional
scales (physical, role, emotional, social, and cognitive), eight
symptom scales (fatigue, nausea and vomiting, pain, insom-
nia, appetite loss, constipation, diarrhea), financial impact of
the disease, and a global health status/QoL scale. Additionally,
the EORTC QLQ-PR25 (25 items) was used for assessing
specific prostate cancer symptoms related to treatment such
as sexual function and activity and bladder and bowel prob-
lems [24]. The items have response categories with four levels
from Bnot at all^ to Bvery much,^ except for two items, which
use seven levels from Bvery poor^ to Bexcellent.^ Higher
scores reflect better functioning in the functional scales as well
as the global health status scale and more symptoms (urinary,
bowel, hormonal treatment-related symptoms) as well as
higher levels of sexual functioning.
SOC
The SOC scale developed by Antonovsky [25] assesses a
person’s overall orientation to life, as an inner resource for
coping with stressful life events. The SOC concept is built
on how comprehensible, manageable, and meaningful life ap-
pears. The scale consists of 13 items that comprise three com-
ponents: comprehensibility (to which 5 items contribute),
manageability (4 items), and meaningfulness (4 items). The
respondents indicate agreement or disagreement on a 7-
category scale, with two anchoring responses tailored to the
content of each item. Five items are reversed before summing
the total score. The total score can range from 13 to 91, and a
higher score indicates a higher SOC. The scale has been trans-
lated into more than 33 languages and been tested for reliabil-
ity and validity, as well as for cross-cultural adaptation in
several settings, while using cohorts both from within health
care facilities and from the general populations in different
countries [26]. Studies show that a high SOC is correlated to
better health and HRQoLwithin different samples [27] as well
as in men with prostate cancer [28].
Statistical analysis
Chi-square statistics were performed to compare proportions
of categorical variables. The items of the EORTC QLQ-C30
and the EORTC QLQ-PR25 were scaled according to the
scoring manual, and raw scores were linearly transformed into
0–100 scales [29]. Both within-group and between-group
analyses were performed. The variables in the functional and
symptom scales, which in a Student’s t test showed significant
mean differences between the groups (Table 3), were run in
general linear model (GLM) repeated measures as dependent
variables with group as a factor. Because Beducation^ showed
significant group difference (p = 0.017) at baseline (Table 1),
we included this as a covariate in the analyses. Subsequently,
with regard to the predictive validity, the SOC has shown in
longitudinal studies for a good HRQoL [27, 30], additional
GLM repeated measure analyses were performed while also
adding SOC as a covariate. Statistical calculations were per-
formed using the Statistical Package for Social Sciences,
Windows version 22.0. A statistical significance level of
p < 0.05 was applied in all analyses.
Results
The IG and the CG were well balanced regarding demo-
graphics and clinical characteristics, except that the CG
showed a statistically significant lower level of education
(Table 1). At baseline (T1), there were no statistically signif-
icant differences between the IG and the CG regarding any of
the outcome measures (Table 2).
Differences within groups
There were no significant differences regarding the functional
scales within the IG over time: from T1 to T3. Meanwhile, the
patients in the CG rated significantly decreased global quality of
life (p = 0.015) and role (p = 0.004), as well as emotional
(p = 0.026) and social (p = 0.004) functioning. Regarding the
symptom scales over time, the CG reported increased fatigue
(p = 0.001) and insomnia (p = 0.05). Both groups reported a
significant increase of diarrhea, urinary symptoms, bowel symp-
toms, hormone-related symptoms, and sexual activity (Table 2).
Differences between groups
The CG rated significantly worse emotional functioning at the
end of the radiotherapy (p = 0.002), as well as 3 months later
(p = 0.26) compared with the IG. The CG also had a higher
level of fatigue (p = 0.047) and nausea (p = 0.038) at the end
Support Care Cancer
of treatment. Insomnia and urinary symptoms were more fre-
quently reported by the CG both at the end of treatment
(p = 0.005 and p = 0.005, respectively) and 3 months later
(p = 0.035 and p = 0.038, respectively) (Table 2).
In the multivariate analyses, with education as a covariate,
the IG still significantly rated emotional functioning
(p = 0.007), insomnia (p = 0.004), and urinary-related symp-
toms (p = 0.003) as better than the CG at T2.When adding the
SOC scale as a covariate, SOC was a significant predictor in
the dependent scales, except for nausea at T2, and the statisti-
cally significant differences for emotional functioning
(p = 0.007), insomnia (p = 0.017), and urinary-related symp-
toms (p = 0.008) at T2 remained. Thus, the IG rated better
emotional functioning and fewer problems with sleep and
urinary symptoms than the CG did at the end of treatment
(Table 3). An illustration of the findings is presented in Fig. 2.
Discussion
This study provides novel results for the effects on symp-
tom burden and HRQoL when using a smartphone app for
real-time symptom assessment and management during
treatment in patients with localized prostate cancer. The
main finding was that the intervention group reported less
symptom burden at the end of treatment in emotional
functioning, insomnia, and urinary-related symptoms
compared to the control group. Furthermore, within-
Table 2 Between- and within-group differences in mean scores of EORTCQLQ-C30 + EORTCQLQ-PR 25 and SOC in intervention group (IG) and
control group (CG)
T1 T2 T3
IG (n = 64) CG (n = 62) p IG (n = 51) CG (n = 59) p IG (n = 61) CG (n = 55) p P-a P-b
EORTC QLQ-C30
mean (SD)
Global QoL 74.9 (20.2) 71.9 (17.1) .377 69.8 (20.5) 66.0 (19.1) .315 74.2 (18.8) 69.2 (19.2) .165 .015
Finance 8.9 (23.2) 9.0 (44.1) .982 14.4 (32.1) 5.1 (17.3) .057 6.0 (18.8) 6.0 (18.1) .986 .004
Functional scales
Physical 90.7 (13.3) 87.6 (15.3) .228 87.1 (16.8) 85.5 (15.8) .598 87.6 (17.9) 83.9 (17.2) .277
Role 86.5 (21.4) 86.5 (20.7) .999 79.2 (27.4) 75.8 (25.6) .911 84.2 (23.7) 82.4 (24.1) .312 .004
Emotional 85.6 (17.6) 80.8 (19.6) .155 90.2 (18.4) 77.7 (22.2) .002 90.0 (18.0) 82.6 (17.6) .026 .026
Cognitive 87.8 (18.1) 88.3 (14.5) .838 86.9 (16.7) 86.0 (16.3) .763 86.6 (2.1) 85.7 (13.6) .746
Social 79.7 (23.1) 85.8 (16.3) .092 77.5 (21.8) 75.3 (22.7) .619 78.3 (23.0) 80.1 (21.9) .680 .004
Symptom scales
Fatigue 20.1 (18.8) 23.8 (19.0) .274 25.7 (21.5) 34.3 (22.9) .047 22.8 (19.5) 29.4 (19.9) .073 .001
Nausea 1.6 (5.7) 1.6 (5.0) .979 1.7 (5.9) 5.3 (11.7) .038 3.0 (13.8) 3.3 (9.2) .882
Pain 17.5 (23.5) 15.1 (20.7) .547 19.0 (24.9) 21.9 (22.1) .512 13.7 (20.5) 17.9 (24.1) .312
Dyspnea 21.4 (24.8) 19.0 (23.7) .593 23.3 (27.7) 20.0 (21.4) .462 24.6 (25.7) 18.8 (22.0) .197
Insomnia 22.9 (26.5) 25.4 (26.6) .599 18.6 (25.7) 33.9 (32.2) .005 18.6 (24.7) 29.6 (30.8) .035 .051
Appetite 5.2 (17.0) 4.2 (16.4) .743 5.6 (20.5) 7. 2 (17.5) .633 4.4 (15.5) 4.3 (11.3) .984
Constipation 6.8 (18.0) 10.0 (19.5) .326 10.0 (20.6) 16.1 (26.4) .160 6.6 (17.0) 9.1 (19.7) .459
Diarrhea 6.3 (14.4) 7.4 (17.4) .683 20.3 (25.9) 24.9 (30.7) .402 12.0 (20.2) 13.7 (20.9) .661 .027 .017
EORTC QLQ-PR 25
mean (SD)
Sexual activity 76.3 (22.9) 77.3 (23.7) .817 85.0 (17.4) 85.1 (18.0) .958 82.8 (18.2) 86.3 (18.2) .310 .025 .004
Sexual function 61.7 (14.8) 55.7 (14.5) .412 60.9 (17.5) 55.6 (18.5) .442 51.7 (15.7) 53.7 (21.3) .750
Urinary symptoms 16.4 (14.1) 20.0 (15.9) .176 32.1 (19.4) 43.6 (23.1) .005 20.6 (15.5) 27.6 (19.9) .038 .025 .002
Bowel symptoms 5.1 (8.5) 4.1 (7.9) .494 11.6 (12.3) 15.7 (17.0) .141 8.1 (12.9) 7.9 (9.2) .934 .028 .018
Hormone related 19.7 (13.5) 18.1 (16.1) .574 21.4 (10.9) 22.2 (15.5) .736 25.7 (14.1) 26.5 (15.5) .772 .001 .002
Incontinence aid 0.0 15.1 (23.0) .541 16.7 (18.2) 22.2 (20.6) .572 16.7 (19.2) 7.4 (14.7) .358
SOC
mean (SD) 74.9 (11.3) 71.5 (11.2) .116 74.2 (9.8) 72.0 (12.3) .283 74.1 (11.2) 72.3 (11.9) .433
P-a IG over time, P-b CG over time
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group findings showed that the control group was more
negatively affected by treatment over time as compared
with the intervention group.
Our results confirm optimistic outcomes at the end of
treatment when using the application, although results are
not persistent at the 3-month follow-up. However, there
was also a trend of better scores in many of the symptom
and functional scales at 3 months post-treatment. This is
an encouraging finding, as patients who experience a high
symptom burden are more at risk of developing symptom-
related distress [6]. Also, urinary problems such as incon-
tinence and urinary urgency have been shown to be very
common long-lasting symptoms after treatment with a
negative influence on HRQoL [2, 31].
Sleeping problems studied in patients with non-
metastatic cancer have been shown to be strongly asso-
ciated with anxiety and depression [32]. In a recent re-
view of supportive care during and after treatment of
prostate cancer, men described an increased need for
emotional support when experiencing treatment side ef-
fects [33]. Early identification and management of symp-
toms might be especially important, as under-diagnosed
symptoms often have a negative impact on the individ-
ual’s HRQoL and recovery, and last for a long time after
treatment [34]. Reporting symptoms daily enabled instant
support from a nurse when needed. When the nurses
received an alert, the patient was contacted and they
discussed how the problem could be alleviated. If the
patient needed a medication, the nurse consulted a doc-
tor. In other cases, nursing actions, by either seeing the
patient or talking on the phone, were instigated. The self-
care advice directly related to the reported concerns was
another important asset that could enable the patients to
take an active part. Guiding patients with cancer in self-
care management is essential for functional status and
HRQoL [35]. In our previous study, we found that strat-
egies for self-care management for patients with prostate
cancer are rare in the literature, and in interviews with
patients, they expressed scarce experience of support or
information about self-care activities during treatment
[5]. Furthermore, the patients reported that it was some-
times difficult to get in touch with health care profes-
sionals and that they were lacking sufficient information
about their symptoms. In their review, Mazzarello et al.
[33] also showed that the men reported poor communi-
cation with health professionals about the potential sever-
ity and duration of their symptoms. This highlights the
urgent need for improved access to cancer specialist
nurses, as well as individually tailored supportive care
for treatment of side effects. In person-centered care em-
phasis is on the interaction between the patient and the
health care givers enabling the patient to be a partner
rather than a passive receiver of care [36]. A mHealth
tool like Interaktor could be a facilitator for person-
centered care, and it can be used in a wide range of
settings tailored to suit any group of patients.
A methodological consideration is the potential con-
founders not controlled for following the design. A ran-
domly assigned sample is of course optimal, although the
spillover effect must always be taken into account. Still,
the treatment regime and the standard clinical procedures,
having access to doctors and nurses, were the same for
both groups of patients. The two groups were comparable
in many variables except that educational level in the
control group was significantly lower than in the interven-
tion group, which may influence their ratings of self-
reported HRQoL. Strength is, however, when controlling
for educational level as well as the patients’ degree of
SOC, both strongly related to HRQoL [27, 37], the group
effect remained in one functional and two symptom
scales. In recent literature, there is a general view that
educational level is not really a holdback for using
mHealth but rather a significant factor for satisfaction of
such use [38]. Literature also reveals health literacy to be
a factor for processing the meaning and usefulness of
health information and services [20, 39]. In our study,
the degree of health literacy was not significantly different
between the groups at baseline indicating that they were
equally prone to understand and adhere to standard care
of symptom management [20]. Still, due to lack of famil-
iarity of technology mobile-based symptom, reporting
may not be feasible for all patients which should be taken
into account for future implementation.
Table 3 General linear model test between subjects
Group Education SOC Model
p p p Adj R2
Emotional T1 .810 .447 .000 .229
Emotional T2 .007 .712 .000 .355
Emotional T3 .506 .332 .000 .248
Fatigue T1 .999 .982 .000 .102
Fatigue T2 .128 .727 .000 .237
Fatigue T3 .218 .765 .000 .153
Nausea T1 .718 .935 .024 .022
Nausea T2 .331 .505 .131 .015
Nausea T3 .942 .718 .000 .122
Insomnia T1 .376 .285 .000 .110
Insomnia T2 .017 .795 .001 .140
Insomnia T3 .213 .551 .002 .092
Urinary symptoms T1 .900 .069 .000 .137
Urinary symptoms T2 .008 .832 .001 .169
Urinary symptoms T3 .303 .174 .000 .167
Analyzed by multivariate tests with group as factor and education and
SOC as covariates
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Few studies discuss clinical as well as cost effectiveness in
relation to mHealth [39] which is imperative before
implementing in clinical care. We show that using our app
render less symptom burden, which confirms a concrete value
for the patients. Patient satisfaction of using the app warrants
further investigation although high acceptability and user-
friendliness of the app were previously shown in our feasibil-
ity studies [17, 40]. However, evaluations in full RCT studies
are required before general implementation.
In conclusion, reporting symptoms via the application
seems to have had a positive effect on symptom burden and






































Fig. 2 Between-group ratings of
quality of life and symptoms from
the EORTC questionnaire
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interactive application like Interaktor is unique, with its real-
time communication enabling rapid management of symp-
toms when detected early. Our findings suggest that
Interaktor could be an efficient mHealth tool for facilitating
support needs during radiotherapy for prostate cancer.
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